Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals

Table 1 Patient characteristics.

	HIV	HIV/HCV	Chronic HCV
Number (n)	24	10	3
Age (yrs ± SD)	41.7 ± 7.0	39.2 ± 3.85	49 ± 15
Sex (%)
M	75	80	66
F	25	20	33
HCV Genotype (%)
1	N/A	100	0
Non-1	N/A	0	0
Unknown	N/A	0	100
HCV status (%)
Chronic infection (HCV RNA +)	N/A	80	100
Clearance (HCV RNA -)	N/A	20	0
HCV Risk Factor (%)
IVDU	N/A	30	66.7
Transfusion	N/A	20	33.3
Tattoo	N/A	0	0
Endemic area	N/A	0	0
Unknown	N/A	40	0
Estimated duration of infection (yrs ± SD) ¹
HIV	18 ± 5.1	10 ± 2.1	N/A
HCV	N/A	18 ± 3.4	24 ± 8
Antiviral therapy (%)
HIV	58	90	N/A
HCV	N/A	0	0
Suppressed viral load ² (%)
HIV	75	70	N/A
HCV	N/A	20%	Unk.
CD4⁺ T cell count³ (median cells/μL, interquartile range)	409, 422	608, 80	N/A
CD4⁺ T cell nadir⁴ (median cells/μL, interquartile range)	252, 296	247, 350	N/A

Abbreviations: Avg average; N/A not applicable; SD standard deviation. ¹The time since clinically confirmed infection or, in the case of HCV, high risk activity. ²Undetectable viral load by Roche Amplicor RT-PCR test for HIV and in house PCR for HCV at the time of participation. This also includes those who have spontaneously cleared the virus in the case of HCV. ³Measured on the day of participation. ⁴Lowest documented count over the course of followup.

ISSN: 1471-2172